Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 1.02 Billion USD | -19.54% |
| 2023 | 1.27 Billion USD | 3.22% |
| 2022 | 1.23 Billion USD | 5.38% |
| 2021 | 1.17 Billion USD | 11.23% |
| 2020 | 1.05 Billion USD | 3.34% |
| 2019 | 1.02 Billion USD | -1.84% |
| 2018 | 1.04 Billion GBP | 0.57% |
| 2017 | 1.03 Billion GBP | 4.86% |
| 2016 | 988.02 Million GBP | 53.35% |
| 2015 | 644.3 Million GBP | 10.29% |
| 2014 | 584.2 Million GBP | -4.29% |
| 2013 | 610.4 Million GBP | 3.13% |
| 2012 | 591.9 Million GBP | 8.59% |
| 2011 | 545.1 Million GBP | 0.5% |
| 2010 | 542.4 Million GBP | 8.94% |
| 2009 | 497.9 Million GBP | 14.2% |
| 2008 | 436 Million GBP | 0.28% |
| 2007 | 434.8 Million GBP | -4.71% |
| 2006 | 456.3 Million GBP | 336.23% |
| 2005 | 104.6 Million GBP | 10.09% |
| 2004 | 95.01 Million GBP | -6.6% |
| 2003 | 101.72 Million GBP | 7.18% |
| 2002 | 94.91 Million GBP | -8.74% |
| 2001 | 104 Million GBP | 0.64% |
| 2000 | 103.34 Million GBP | 118.15% |
| 1999 | 47.37 Million GBP | 22.64% |
| 1998 | 38.62 Million GBP | 5.33% |
| 1997 | 36.67 Million GBP | 13.73% |
| 1996 | 32.24 Million GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 1.3 Billion USD | 1.72% |
| 2024 Q3 | 1.02 Billion GBP | -23.31% |
| 2024 Q1 | 1.05 Billion GBP | -17.59% |
| 2024 Q2 | 1.34 Billion GBP | 27.3% |
| 2024 Q4 | 1.02 Billion GBP | 0.0% |
| 2023 Q3 | 1 Billion GBP | -18.65% |
| 2023 Q4 | 1.27 Billion USD | 26.93% |
| 2023 Q2 | 1.23 Billion USD | 20.94% |
| 2023 FY | 1.27 Billion USD | 3.22% |
| 2023 Q1 | 1.02 Billion GBP | 0.61% |
| 2022 Q1 | 896.2 Million GBP | -23.77% |
| 2022 Q2 | 896.2 Million GBP | 0.0% |
| 2022 Q3 | 1.01 Billion GBP | 13.58% |
| 2022 Q4 | 1.01 Billion GBP | 0.0% |
| 2022 FY | 1.23 Billion USD | 5.38% |
| 2021 Q3 | 851 Million GBP | -26.04% |
| 2021 Q4 | 1.17 Billion GBP | 38.15% |
| 2021 Q1 | 841.7 Million GBP | -21.58% |
| 2021 Q2 | 1.15 Billion GBP | 36.69% |
| 2021 FY | 1.17 Billion USD | 11.23% |
| 2020 FY | 1.05 Billion USD | 3.34% |
| 2020 Q1 | 839 Million GBP | -20.01% |
| 2020 Q4 | 1.07 Billion GBP | 25.48% |
| 2020 Q3 | 855.4 Million GBP | -23.04% |
| 2020 Q2 | 1.11 Billion GBP | 32.48% |
| 2019 Q3 | 803.6 Million GBP | 0.1% |
| 2019 FY | 1.02 Billion USD | -1.84% |
| 2019 Q1 | 802.8 Million GBP | 1.72% |
| 2019 Q2 | 802.8 Million GBP | 0.0% |
| 2019 Q4 | 1.04 Billion GBP | 30.52% |
| 2018 Q1 | 775 Million GBP | -2.83% |
| 2018 Q3 | 789.2 Million GBP | 1.83% |
| 2018 Q4 | 789.2 Million GBP | 0.0% |
| 2018 FY | 1.04 Billion GBP | 0.57% |
| 2018 Q2 | 775 Million GBP | 0.0% |
| 2017 Q4 | 797.6 Million GBP | 0.0% |
| 2017 FY | 1.03 Billion GBP | 4.86% |
| 2017 Q3 | 797.6 Million GBP | -1.65% |
| 2017 Q2 | 811 Million GBP | 0.0% |
| 2017 Q1 | 811 Million GBP | 9.73% |
| 2016 Q1 | 670.2 Million GBP | 4.02% |
| 2016 Q3 | 739.1 Million GBP | 10.28% |
| 2016 Q4 | 739.1 Million GBP | 0.0% |
| 2016 FY | 988.02 Million GBP | 53.35% |
| 2016 Q2 | 670.2 Million GBP | 0.0% |
| 2015 Q2 | 642.4 Million GBP | 0.0% |
| 2015 Q1 | 642.4 Million GBP | 9.96% |
| 2015 FY | 644.3 Million GBP | 10.29% |
| 2015 Q3 | 644.3 Million GBP | 0.3% |
| 2015 Q4 | 644.3 Million GBP | 0.0% |
| 2014 Q1 | 609.4 Million GBP | -0.16% |
| 2014 FY | 584.2 Million GBP | -4.29% |
| 2014 Q4 | 584.2 Million GBP | 0.0% |
| 2014 Q2 | 609.4 Million GBP | 0.0% |
| 2014 Q3 | 584.2 Million GBP | -4.14% |
| 2013 Q2 | 587.3 Million GBP | 0.0% |
| 2013 Q3 | 610.4 Million GBP | 3.93% |
| 2013 FY | 610.4 Million GBP | 3.13% |
| 2013 Q4 | 610.4 Million GBP | 0.0% |
| 2012 Q2 | 560.8 Million GBP | 0.0% |
| 2012 FY | 591.9 Million GBP | 8.59% |
| 2012 Q4 | 591.9 Million GBP | 0.0% |
| 2011 Q4 | 545.1 Million GBP | 0.0% |
| 2011 FY | 545.1 Million GBP | 0.5% |
| 2011 Q2 | 543 Million GBP | 0.0% |
| 2010 Q4 | 542.4 Million GBP | 0.0% |
| 2010 Q2 | 525.7 Million GBP | 0.0% |
| 2010 FY | 542.4 Million GBP | 8.94% |
| 2009 Q4 | 497.9 Million GBP | 0.0% |
| 2009 FY | 497.9 Million GBP | 14.2% |
| 2009 Q2 | 550 Million GBP | 0.0% |
| 2008 FY | 436 Million GBP | 0.28% |
| 2008 Q4 | 436 Million GBP | 0.0% |
| 2008 Q2 | 446.4 Million GBP | 0.0% |
| 2007 Q4 | 434.8 Million GBP | 0.0% |
| 2007 Q2 | 434.2 Million GBP | 0.0% |
| 2007 FY | 434.8 Million GBP | -4.71% |
| 2006 Q3 | 316.87 Million GBP | 0.0% |
| 2006 FY | 456.3 Million GBP | 336.23% |
| 2006 Q1 | 106.56 Million GBP | 0.0% |
| 2005 FY | 104.6 Million GBP | 10.09% |
| 2005 Q1 | 105.19 Million GBP | 0.0% |
| 2005 Q3 | 104.6 Million GBP | 0.0% |
| 2004 FY | 95.01 Million GBP | -6.6% |
| 2004 Q3 | 95.01 Million GBP | 0.0% |
| 2004 Q1 | 102.65 Million GBP | 0.0% |
| 2003 FY | 101.72 Million GBP | 7.18% |
| 2002 FY | 94.91 Million GBP | -8.74% |
| 2001 FY | 104 Million GBP | 0.64% |
| 2000 FY | 103.34 Million GBP | 118.15% |
| 1999 FY | 47.37 Million GBP | 22.64% |
| 1998 FY | 38.62 Million GBP | 5.33% |
| 1997 FY | 36.67 Million GBP | 13.73% |
| 1996 FY | 32.24 Million GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -44541025.541% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -52443.447% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -9648.91% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -186254.416% |
| Rebus Holdings, Inc. | 5000.00 USD | -20577900.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -690.181% |
| Qrons Inc. | 420.00 USD | -244976090.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -133411.712% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -3582.007% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -214005.715% |
| Skye Bioscience, Inc. | 11.94 Million USD | -8516.956% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -2548.596% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -14151.162% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1347439.094% |
| SQZ Biotechnologies Company | 107.18 Million USD | -859.911% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -71748.953% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1421719.941% |
| Mesoblast Limited | 667.9 Million USD | -54.05% |
| Marizyme, Inc. | 22.01 Million USD | -4573.616% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -75646.143% |
| Pharming Group N.V. | 462.85 Million USD | -122.295% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -30956.332% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -206076.271% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -163998.884% |
| ContraFect Corporation | 20.67 Million USD | -4875.579% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -263473.16% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -269120.806% |
| IMV Inc. | 31.33 Million USD | -3183.676% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -24716.559% |
| MultiCell Technologies, Inc. | 126.22 USD | -815163899.366% |
| ONE Bio Corp. | 70.08 Million USD | -1368.064% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -109393.673% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -700.638% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -238229.079% |
| Q BioMed Inc. | 3.51 Million USD | -29167.388% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -2824.756% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -393696.622% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1393714.601% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -130.535% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -70915.286% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -3327.958% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -37364.475% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -149561.229% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -39424.492% |
| GB Sciences, Inc. | 103.44 Thousand USD | -994563.676% |
| Alpha Cognition Inc. | 2.45 Million USD | -41858.755% |
| HST Global, Inc. | 1526.00 USD | -67424539.581% |
| CSL Limited | 38.02 Billion USD | 97.294% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -104043.155% |
| Halberd Corporation | 10.13 Thousand USD | -10155856.964% |
| Enzolytics Inc. | 361.7 Million USD | -184.457% |
| Agentix Corp. | 261.39 Thousand USD | -393523.37% |
| Resverlogix Corp. | 8.11 Million USD | -12578.99% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -54690.508% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 77.349% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -2056.933% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -160752.083% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -4516383.034% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -11397.175% |
| AVAX Technologies, Inc. | 7.37 Million USD | -13847.107% |
| Zenith Capital Corp. | 7410.00 USD | -13885190.148% |
| Genscript Biotech Corporation | 3.38 Billion USD | 69.617% |
| Ember Therapeutics, Inc. | 184.00 USD | -559184682.609% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -319626.792% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -393565.539% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -110777.505% |
| Kadimastem Ltd | 2.3 Million USD | -44555.568% |
| Helix BioMedix, Inc. | 3.02 Million USD | -33912.256% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -1852.335% |
| BioStem Technologies, Inc. | 14.56 Million USD | -6966.48% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1802015.809% |
| LadRx Corporation | 2.3 Million USD | -44482.002% |
| Cell Source, Inc. | 195.17 Thousand USD | -527078.73% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -290864.518% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -290864.518% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1652804.511% |
| Affymax, Inc. | 7.44 Million USD | -13723.727% |
| Itoco Inc. | 1.4 Million USD | -73389.078% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1075513.912% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -970560.377% |
| Mobile Lads Corp. | 52.00 USD | -1978653746.154% |
| CytoDyn Inc. | 11.13 Million USD | -9139.404% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -719551.4% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -5754374.273% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -266820.209% |
| SYBLEU INC | 330.46 Thousand USD | -311246.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -251205.499% |
| International Stem Cell Corporation | 5.39 Million USD | -18989.054% |
| Bioxytran, Inc. | 137.63 Thousand USD | -747440.65% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -6758.497% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -6106.044% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1302305.063% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -118892.41% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -13587.641% |
| Neutra Corp. | 2851.00 USD | -36088991.547% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -3075.029% |
| PureTech Health plc | 693.97 Million USD | -48.262% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -12647.97% |
| IXICO plc | 15.84 Million USD | -6393.981% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -12323.328% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -895.8% |
| CSL Limited | 38.02 Billion USD | 97.294% |
| Cellectis S.A. | 333.99 Million USD | -208.059% |